Printer Friendly

ArQule, Inc. and The R. W. Johnson Pharmaceutical Research Institute Add Compass Array(TM) Library to Collaboration Agreement.

WOBURN, Mass., Sept. 19 /PRNewswire/ --

ArQule, Inc. (Nasdaq: ARQL) announced today an amendment of their 1998 collaboration agreement with The R.W. Johnson Pharmaceutical Research Institute ("PRI"), a Johnson & Johnson Company, to discover new lead compounds for a variety of therapeutic areas. The amended agreement includes the addition of ArQule's Compass Array(TM) libraries, which can be screened by PRI and other Johnson & Johnson companies.

"We are pleased that our collaboration with PRI continues to meet their expectations. The addition of our novel Compass Array libraries demonstrates our commitment to helping our collaborators improve the efficiency of their drug discovery programs," said Stephen Hill, CEO and President of ArQule.

Under the amended agreement, PRI will continue to have access to ArQule's Mapping Array compounds already provided to PRI since the initiation of the four-year agreement and will now have access to ArQule's new Compass Array libraries through the conclusion of the collaboration in 2001. Each Compass Array library is a diverse set of compounds selected from and representing each array within ArQule's Mapping Array(R) repository. The Compass Array program is designed to reduce drug discovery costs by identifying those arrays contained within ArQule's Mapping Array repositories that warrant further evaluation without the need to screen the entire compound collection. The Compass Array libraries will be provided in lieu of other deliverables, resulting in no changes to the financial terms of the original agreement.

ArQule offers products and services that improve the efficiency and effectiveness of the drug discovery process including accelerated lead optimization services, novel, diverse screening libraries, and access to their high-throughput parallel synthesis platform through technology licensing agreements. In addition, ArQule participates in joint drug discovery programs with selected biotechnology and academic partners. For additional information, please visit www.arqule.com.

Statements in this press release that are not strictly historical are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. The actual results may differ from those projected in the forward looking statement due to risks and uncertainties that exist in the Company's operations, development efforts and the business environment. These risks and uncertainties are described more fully in the Company's annual report and Form 10-K for the year ended December 31, 1999 filed with the Securities and Exchange Commission.

ArQule Contact:

Stephen Hill, CEO and President

(781) 994-0300

www.arqule.com

Investor Relations Contact:

Douglas E. MacDougall

Feinstein Kean Healthcare

(617) 577-8110
COPYRIGHT 2000 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:1USA
Date:Sep 19, 2000
Words:401
Previous Article:PR Newswire Pittsburgh Daybook for Tuesday, September 19.
Next Article:PR Newswire Minneapolis/St. Paul Daybook for Tuesday, September 19.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters